Latest advances in cannabinoid receptor antagonists and inverse agonists

被引：37
作者：
Muccioli, Giulio G.
Lambert, Didier M.
机构：
[1] Univ Catholique Louvain, Drug Design & Discovery Ctr, B-1200 Brussels, Belgium
[2] Univ Catholique Louvain, Unite Chim Pharmaceut & Radiopharm, B-1200 Brussels, Belgium
[3] Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA
来源：
EXPERT OPINION ON THERAPEUTIC PATENTS | 2006年 / 16卷 / 10期
关键词：
cannabinoid; CB1; antagonists; CB1 inverse agonist; CB2; inverse agonists; JTE-907; SR141716; SR147778; SLV319; Sch225336;
D O I：
10.1517/13543776.16.10.1405
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
This review covers the progress made in the field of CB1 and CB2 cannabinoid receptor antagonists and inverse agonists since 2004. The high therapeutic potential of these compounds is reflected by the great number of patents filed during the last 3 years. Although the vast majority of the patents are related to CB1 due to the known therapeutic potential of CB1 antagonists, several compounds acting at CB2 have also been disclosed. Obesity, metabolic syndrome and smoking cessation are CB1 antagonists indications supported by the recent clinical trials results.
引用
收藏
页码：1405 / 1423
页数：19
相关论文
共 172 条
[1]  
ACHARD D, 2001, Patent No. 200164632
[2]  
Adam J, 2002, EXPERT OPIN THER PAT, V12, P1475
[3]  
ALANINE A, 2004, Patent No. 2004013120
[4]  
Allen J.R., 2005, [No title captured], Patent No. [WO2005066126, 2005066126, WO2005/ 066126A1]
[5]  
ANTEL J, 2005, Patent No. 2005039566
[6]  
Antel J., 2005, [No title captured], Patent No. [2005039579, WO2005039579-A1]
[7]  
Armstrong H. M., 2005, [No title captured], Patent No. [WO 2005027837 A2, 2005027837]
[8]  
ASTRAZENECA AB, 2004, Patent No. 2004111034
[9]  
ASTRAZENECA AB, 2004, Patent No. 2004111033
[10]  
ASTRAZENECA AB, 2005, Patent No. 2004058255
12345678910